Navigation Links
DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments
Date:3/31/2009

ached agreement with the FDA on the design of a confirmatory, pivotal Phase 3 clinical trial evaluating its lead product orBec(R) for the treatment of acute GI GVHD. The agreement was made under the FDA's Special Protocol Assessment (SPA) procedure.

About DOR BioPharma, Inc.

DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. DOR expects to begin a confirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI GVHD and a Phase 1/2 clinical trial of DOR201 in radiation enteritis in the second half of 2009. orBec(R) is also currently the subject of an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Oral BDP may also have application in treating other gastrointestinal disorders characterized by severe inflammation. Additionally, DOR has a Lipid Polymer Micelle (LPM(TM)) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.

Through its Biodefense Division, DOR is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, RiVax(TM), has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers.

For further information regarding DOR BioPharma, Inc., please visit t
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... (PRWEB) July 11, 2014 BCC Research ... DIGITAL POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS ... (PCR) technology reached nearly $140 billion in 2013. This ... registering a five-year compound annual growth rate (CAGR) of ... number of interesting and exciting possibilities within the broader ...
(Date:7/11/2014)... -- Researchers have pioneered a revolutionary new way to ... Virtual Finger, allows scientists to move through digital ... using the flat surface of their computer screens. ... orders of magnitude more efficient, saving time, money ... areas of experimental biology. The software and its ...
(Date:7/10/2014)... 10, 2014 Product and process ... low abundance and are often “lost in the ... , Join presenters Dr. Rowel Tobias, Senior Scientist, ... Anders, Head of Quality at Nanotherapeutics, Inc., to ... can speed detection and quantitation while achieving the ...
(Date:7/10/2014)... Mass. (PRWEB) July 10, 2014 Terascala, ... today announced that Alan Swahn, a former vice president ... executive team as vice president of marketing. Terascala’s software ... Dell and NetApp create the highest performance and most ... been appointed to guide Terascala’s channel expansion and broaden ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... EMERYVILLE, Calif. , May 4 S*BIO Pte Ltd and ... their development collaboration and option and license commercialization agreement for S*BIO,s novel ... 0805, respectively. The expanded agreement builds upon the development and commercialization collaboration ... , , ...
... 4 Romark Laboratories announced results from its STEALTH C-3 ... patients with genotype 1 chronic hepatitis C.  Study results were presented ... of the American Gastroenterological Association Institute (AGA Institute) during Digestive Disease ... , , ...
... ... Sepha , is challenging traditional thinking on leak testing procedures through ... its new leak-testing technology can increase competiveness and revolutionise current packaging test methods within ... ...
Cached Biology Technology:S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 2S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 3S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 4S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 5Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 2Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 3Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 4Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 5Pharmaceutical Leak Testing Practices challenged by SEPHA 2Pharmaceutical Leak Testing Practices challenged by SEPHA 3
(Date:7/11/2014)... evidence has demonstrated that transplantation of mesenchymal stem cells ... or mouse models of Alzheimer,s disease (AD) and improve ... ischemia. Few studies are reported on the therapeutic effect ... AD and on the effect on oxidative injury and ... Yan and her team, School of Life Sciences, Tsinghua ...
(Date:7/11/2014)... cannabinoid receptor type 1 can inhibit voltage-gated ... reduce neurotransmitter release. However, some scholars demonstrated ... extracellular Ca2+ influx and increase neurotransmitter release. ... Hospital Affiliated to Tongji Medical College, Huazhong ... whole cell voltage-clamp and calcium imaging in ...
(Date:7/11/2014)... In the brains of all vertebrates, information is ... electric or chemical signal to be passed from ... are the most abundant type of synapse, can ... crucial for learning, memory, perception and cognition, and ... for brain function. For instance, every time ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2
... U.S. agricultural practices create 58 percent of nitrous oxide ... gas in the atmosphere. Scientists believe nitrous oxide contributes to ... practices and products have been introduced to address this issue, ... to experiment with ideas that may ultimately hurt the "bottom ...
... considered overweight and more than one-third categorized as obese, ... is a major national goal. Mathematical modeling of the ... growing subfield of obesity research, which can be used ... Mathematical and Biological Synthesis (NIMBioS) is now accepting applications ...
... available in German . , "Don,t be a frog!" ... away. However to be called a frog should actually be a ... at least from the point of view of evolutionary biology: ... are superior to all the other amphibians, and even mammals", says ...
Cached Biology News:MU scientists find new farming method to reduce greenhouse gases, increase farm yields 2Body weight regulation and metabolism focus of workshop 2Inventions of evolution: What gives frogs a face 2
... an aqueous solution that contains a purified ... in a MOPS buffer (3-(N-Morpholino) propanesulfonic acid), ... contains a combination of 0.02% methylisothiazolone, 0.02% ... and Haas Company) as a preservative. ...
Preparation Note: by a modification of the procedure of C.W. Hancher et al., Biotechnol. Bioeng. 11, 1055 (1969) Assay: ~ 20 A 260 /mg Solubility: water 10 mg/mL, clear, light-yellow Suitab tst...
Request Info...
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
Biology Products: